Browsing by Author Ramalingam, Suresh

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2016Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trialsBoyer, Michael; Janne, P. A.; Liang, Jane Q.; Mok, T. S. K.; O'Byrne, Kenneth; Paz-Ares, Luis; Ramalingam, Suresh; Sbar, E. I.; Taylor, I.; Zhang, H.; Central Clinical School: MedicineDacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials, Annals of Oncology, vol.27, 3, 2016,pp 423-429
2017Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung CancerLee, Chee Khoon; Ahn, Myung-Ju; Akamatsu, Hiroaki; et al, Various; Garassino, Marina; He, Yong; Kim, Hye; Mok, T. S. K.; Ramalingam, Suresh; Shepherd, Frances; Wu, Yi-long; NH&MRC Clinical Trials CentreOsimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, New England Journal of Medicine, vol.376, 7, 2017,pp 629-640
2012Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung CancerBoyer, Michael; Barrios, Carlos; Blackhall, Fiona; Bover, Isabel; et al, Various; Frank, Richard; Heo, Dae Seog; Krzakowski, Maciej; Park, Keunchil; Ramalingam, Suresh; Rosell, Rafael Costa; Talbot, Denis; Central Clinical School: MedicineRandomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.30, 27, 2012,pp 3337-3344